Anzupgo

Anzupgo cream is the first and only topical pan-JAK inhibitor approved for adults with moderate to severe chronic hand eczema. By targeting the JAK-STAT pathway, it provides effective, steroid-free relief from inflammation, itching, and skin damage, giving patients a safer and more convenient alternative to traditional treatments.

Molecule Details :

  • Molecule Name :

    Delgocitinib
  • Innovator :

    LEO PHARMA AS
  • Approval Date :

    23-Jul-25
  • NCE-1 Date :

    23-Jul-29
  • NCE Date :

    23-Jul-30
  • Dosage Form :

    Topical Cream
  • Strength :

    20MG
  • Therapeutic Category :

    Dermatologic
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    85
  • 2026 :

    94
  • 2027 :

    112
  • 2028 :

    137
  • 2029 :

    169
  • 2030 :

    204
  • 2031 :

    234
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?